Opentrons

Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.

Drug programs can be steered using continually updated evidence and probability-of-success estimates, helping identify patient subgroups and change course during trials.

Pathos AI develops oncology drugs using Foundry, an agentic platform that continuously analyzes clinical evidence to select assets and guide development decisions.

AI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results.

Owkin develops K Pro, an autonomous AI scientist that combines multimodal patient data, specialized agents, and laboratory validation to investigate biomedical questions.